| Active ingredient (INN) | Tocilizumab |
|---|---|
| Brand names | Actemra, Avtozma, RoActemra |
| ATC level 5 | L04AC07 |
| ATC level 4 | L04AC |
| Drug class | Anti-IL-6 receptor monoclonal antibody |
| Therapeutic category | Immunology/Rheumatology |
| Strength | 80mg/4ml · 200mg/10ml · 400mg/20ml IV · 162mg/0.9ml SC |
| Dosage form | concentrate for infusion · solution for injection |
| Route of administration | intravenous · subcutaneous |
| Controlled substance | No |
| Marketing-authorisation holders | Roche Products Pty Ltd, CELLTRION USA, Inc., STADA Arzneimittel AG |
| Registrations on file | 11 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| ACTEMRA SC tocilizumab | 162 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| ACTEMRA SC tocilizumab | 162 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| ACTEMRA tocilizumab | 162 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| ACTEMRA tocilizumab | 200 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| ACTEMRA tocilizumab | 400 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| ACTEMRA tocilizumab | 80 mg | — | 🇦🇺 AU | Roche Products Pty Ltd | Active |
| Tocilizumab-anoh | 80mg/4mL | injection | 🇺🇸 US | CELLTRION USA, Inc. | Active |
| Tocilizumab-anoh | 200mg/10mL | injection | 🇺🇸 US | CELLTRION USA, Inc. | Active |
| Tocilizumab-anoh | 400mg/20mL | injection | 🇺🇸 US | CELLTRION USA, Inc. | Active |
| Tocilizumab-anoh | 162mg/.9mL | injection | 🇺🇸 US | CELLTRION USA, Inc. | Active |
| Tocilizumab STADA | — | — | 🌐 EU | STADA Arzneimittel AG | Active |